Prelude Capital Management, LLC Mirati Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$41.99 - $62.38 $1.51 Million - $2.25 Million	36,021 Added 753.89%	40,799 $2.4 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $132,828 - $216,682	4,778 New	4,778 $208,000
Q4 2020 Feb 16, 2021	SELL	$162.05 - $240.27 $162,860 - $241,471	-1,005 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $113,826 - $168,106	1,005 New	1,005 $167,000
Q1 2020 May 15, 2020	SELL	$69.78 - $116.21 $8,443 - $14,061	-121 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$70.76 - $128.86 $203,222 - $370,085	-2,872 Reduced 95.96%	121 $16,000
Q3 2019 Nov 14, 2019	BUY	$77.91 - $109.6 $233,184 - $328,032	2,993 New	2,993 $233,000
Q4 2018 Feb 14, 2019	SELL	$32.0 - $47.43 $94,432 - $139,965	-2,951 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$47.1 - $62.7 $138,992 - $185,027	2,951 New	2,951 $139,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.